Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 4/20 | 0.32 |
| ▸ | CES1 | P23141 | 4/20 | 0.32 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7839982 | 1.00 | CES2 (0.37) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL5143913 | 1.00 | CES2 (0.37) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL7837031 | 1.00 | CES2 (0.37) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL5071800 | 1.00 | CES2 (0.37) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL3288875 | 1.00 | CES2 (0.37) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL7840276 | 1.00 | CES2 (0.37) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL16892606 | 1.00 | CES2 (0.37) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL3034896 | 0.97 | — | — | |
| SCHEMBL98735 | 0.90 | CES2 (0.46) | CES2GMNNTP53POLBMAPT | |
| SCHEMBL7842773 | 0.90 | CES2 (0.41) | CES2GMNNTP53POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2894685-B1 | BENZOTHIENOBENZOTHIOPHENE DERIVATIVE, ORGANIC SEMICONDUCTOR MATERIAL, AND ORGANIC TRANSISTOR | DAINIPPON INK & CHEMICALS (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-9490433-B2 | Benzothienobenzothiophene derivative, organic semiconductor material, and organic transistor | DIC CORPORATION (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20150228913-A1 | BENZOTHIENOBENZOTHIOPHENE DERIVATIVE, ORGANIC SEMICONDUCTOR MATERIAL, AND ORGANIC TRANSISTOR | DIC CORPORATION (JP) | 2015-08-13 | — | — | US | disclosed |
| EP-2894685-A1 | BENZOTHIENOBENZOTHIOPHENE DERIVATIVE, ORGANIC SEMICONDUCTOR MATERIAL, AND ORGANIC TRANSISTOR | DIC Corporation (JP) | 2015-07-15 | — | — | EP | disclosed |
| EP-0751133-B1 | Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same | MITSUI CHEMICALS INC (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-5770108-A | HIGH SPEED RESPONSE, MOLECULAR ORIENTATION, HIGH CONTRAST, RECEPTIVITY | MITSUI TOATSU CHEMICALS, INC. (JP) | 1998-06-23 | — | — | US | disclosed |
| EP-0751133-A1 | Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150228913-A1 | BENZOTHIENOBENZOTHIOPHENE DERIVATIVE, ORGANIC SEMICONDUCTOR MATERIAL, AND ORGANIC TRANSISTOR | TST, TPST2, TPR | CES2 3225/4885GMNN 2549/4885TP53 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.